| Identification | Back Directory | [Name]
L-Glutamic acid, N-[[[(1S)-1-carboxy-5-[[[(4-iodophenyl)amino]carbonyl]amino]pentyl]amino]carbonyl]- | [CAS]
949575-22-8 | [Synonyms]
MIP1095
MIP-1095
MIP 1095
MIP1095,MIP 1095
L-Glutamic acid, N-[[[(1S)-1-carboxy-5-[[[(4-iodophenyl)amino]carbonyl]amino]pentyl]amino]carbonyl]- | [Molecular Formula]
C19H25IN4O8 | [MOL File]
949575-22-8.mol | [Molecular Weight]
564.33 |
| Hazard Information | Back Directory | [Uses]
MIP-1095 potently inhibits the glutamate carboxypeptidase activity of PSMA (Ki =0.24 nM)[1]. | [References]
[1] Shawn M Hillier, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009 Sep 1;69(17):6932-40. DOI:10.1158/0008-5472.CAN-09-1682 |
|
|